Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutDMDMTrial design and efficacySafety and tolerabilityDosing and infusion ratesPatient profilescITPcITPTrial design and efficacySafety and tolerabilityDosing and infusion ratesMaterialsSupportSupportOCTAGAM 10% Co-Pay ProgramPfizer IGuide™FAQsRequest a RepresentativeIg CompanionCoverage
Prescribing Information, including BOXED WARNINGIndicationsPatient SiteOCTAGAM 5%
Patient profilesDiscover the different types of patients who may benefit from OCTAGAM 10% Monique (66)

Monique had been noticing muscle weakness over several months, leading to her recent DM diagnosis. She is finding that her mobility around the house is now an issue—including reaching for items on shelves, climbing stairs, and more. She is also experiencing skin symptoms associated with DM. 

Treatment needs: Monique is an independent person and doesn’t have anyone nearby to help her. She lives alone and is eager to explore treatment options and address her mobility issues as soon as possible. 

Reach for OCTAGAM 10%—The first and only IVIg FDA approved to treat DM in adults. Clinical trials showed that OCTAGAM 10% helped patients see improvement in muscle and skin symptoms. The median time to response for OCTAGAM 10% is 35 days.1

 Frank (53)

Frank was diagnosed with DM several years ago, and his symptoms range from moderate to severe. He has been actively working with his doctor to try and manage his muscle and skin symptoms. Currently, his physician has prescribed steroids and immunosuppressants, which have not provided enough improvement.

Treatment needs: Clinical data is important to Frank. He wants to be involved in managing and researching treatment options for DM and likes that there is clinical evidence with OCTAGAM 10% demonstrating efficacy and safety. He knows what’s involved with a routine IVIg infusion and is ready to start treatment. 

Reach for OCTAGAM 10%—A Phase 3 clinical trial demonstrated that when OCTAGAM 10% is added to treatments like steroids and immunosuppressants, patients achieved significant improvements in both muscle and skin symptoms at 16 weeks.1

 Sophia (48)

Since her DM diagnosis, Sophia has been working closely with her healthcare team to manage her symptoms. She has been receiving OCTAGAM 10%, which is proving to be a good option for her. However, Sophia is having some financial challenges paying for infusions, even with her commercial insurance. 

Treatment needs: Sophia is responding well to OCTAGAM 10%, but needs a financial assistance program to help with the cost of the drug. 

Learn about OCTAGAM 10% support programs—Eligible, commercially, insured patients may pay as little as $0 for OCTAGAM and may receive a maximum benefit of $12,500 per year. Once a patient reaches the annual maximum benefit patient is responsible for paying the remaining monthly out-of-pocket costs.*

Terms and conditions apply.The OCTAGAM Co-Pay Program provides eligible patients assistance of up to $12,500 per year. Once a patient reaches the annual maximum benefit, patient is responsible for paying the remaining monthly out-of-pocket costs. The OCTAGAM Co-Pay Program is good only in the US and Puerto Rico. No membership fees. Federal and state health care beneficiaries are not eligible. Private insurance only. Eligibility and restrictions apply. See full Terms and Conditions on the Support and financial assistance page. Next page: OCTAGAM 10% in cITP > LoadingReference:Octagam 10%. Prescribing Information. Octapharma USA Inc.; 2023.
Safety and tolerability

Drug-related adverse reactions (ARs) in the clinical trial1

 See data Loading
OCTAGAM 10% Co-Pay Program

With the OCTAGAM Co-Pay Program, eligible patients may pay as little as $0†

 Learn moreLoading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-OTG-USA-0390
You are now leaving PfizerPro YYou are now leaving a Pfizer-operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-OTG-USA-0390
INDICATIONS AND USAGE OCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults.
 Please click here for full Prescribing Information, including BOXED WARNING.
IMPORTANT SAFETY INFORMATION WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE
  • Thrombosis may occur with immune globulin intravenous (IgIV) products, including OCTAGAM 10% liquid. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IgIV products, including OCTAGAM 10% liquid. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IgIV products containing sucrose. OCTAGAM 10% liquid does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer OCTAGAM 10% liquid at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Dosing and Administration Patients with dermatomyositis are at increased risk for thromboembolic events; monitor carefully and do not exceed an infusion rate of 0.04 mL/kg/min. ContraindicationsOCTAGAM 10% liquid is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.Warnings and PrecautionsOCTAGAM 10% liquid may cause hypersensitivity in patients with a corn allergy. OCTAGAM 10% liquid contains maltose, which is derived from corn. Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure. Falsely elevated blood glucose readings may occur during and after the infusion of OCTAGAM 10% liquid with testing by some glucometers and test strip systems. Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving OCTAGAM 10% liquid. Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to treatment with OCTAGAM 10% liquid. Risk factors for hemolysis include high doses and non–O-blood group. Closely monitor patients for hemolysis and hemolytic anemia. Aseptic meningitis syndrome may occur in patients receiving OCTAGAM 10% liquid, especially with high doses or rapid infusion. Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). OCTAGAM 10% liquid is made from human plasma and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease agent. Adverse Reactions cITP - The most common adverse reactions reported in >5% of study subjects were headache, fever, and increased heart rate. DM - The most common adverse reactions reported in >5% of study subjects were headache, fever, nausea, vomiting, increased blood pressure, chills, musculoskeletal pain, increased heart rate, dyspnea, and infusion site reactions.You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly.
Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.OCTAGAM® is a registered trademark of Octapharma AG.Please click here for full Prescribing Information, including BOXED WARNING.INDICATIONS AND USAGEOCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults.